Suven Pharmaceuticals Ltd share price logo

Suven Pharmaceuticals Ltd Share Price

(SUVENPHAR)

Mid Cap

Healthcare Sector

Check the latest share price of Suven Pharmaceuticals Ltd, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.

₹1136.4

▲1.07%

as on 04:01PM, 29 Apr 2025

NSE

bell
The current prices are delayed by 15 mins, login to check live prices.

Suven Pharmaceuticals Ltd Performance

Get real-time share price information, day’s high and low, historical returns and market stats.

  • Day's Low

    Day's High

    ₹1,122
    Day's Price Range
    ₹1,165.9

  • 52 Week's Low

    52 Week's High

    ₹598
    52-Week Price Range
    ₹1,360
1 Month Return+ 1.27 %
3 Month Return+ 8.88 %
1 Year Return+ 83.17 %
Previous Close₹1,148.70
Open₹1,160.00
Volume79.16K
Upper Circuit-
Lower Circuit-
Market Cap₹29,264.79Cr

Suven Pharmaceuticals Ltd Fundamentals & Key Indicators

Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.

Market Cap

₹29,264.79 Cr

Return on Equity (ROE)

43.17

Return on capital employed (ROCE)

51.45

P/B Ratio

10.34

Dividend Yield

0.81

EPS (TTM)

17.83

Sector

Pharmaceuticals

How to invest in Suven Pharmaceuticals Ltd

Investing in Suven Pharmaceuticals Ltd is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Suven Pharmaceuticals Ltd or SUVENPHAR on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

For example: You can buy 10 shares of Suven Pharmaceuticals Ltd or start an SIP based on the market price on each investment date.

You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Suven Pharmaceuticals Ltd with just a few clicks!

Suven Pharmaceuticals Ltd Valuation

Track how the P/E of Suven Pharmaceuticals Ltd has moved over time to understand valuation trends.

Suven Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (4.48x)

March 30, 2020

Today (41.17x)

December 15, 2023

Industry (58.33x)

December 15, 2023

Highest (44.06x)

April 29, 2021

LowHigh

Today’s Price to Earnings Ratio: 41.17x

Analysts Recommendation on Suven Pharmaceuticals Ltd

Get updated buy, sell, and hold recommendations by analysts on Suven Pharmaceuticals Ltd.

based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

100% of analysts recommend a 'BUY' rating for Suven Pharmaceuticals Ltd. Average target of ₹605

Source: S&P Global Market Intelligence

Analysts Forecast on Suven Pharmaceuticals Ltd

Get share price movements and forecasts by analysts on Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd price forecast by 1 analysts

Downside of-47.37%

High

₹605

Target

₹605.00

Low

₹605

Suven Pharmaceuticals Ltd target price ₹605, a slight downside of -47.37% compared to current price of ₹1136.4. According to 1 analysts rating.

Source: S&P Global Market Intelligence

Suven Pharmaceuticals Ltd Financials

Get the annual and quarterly financial summary of Suven Pharmaceuticals Ltd, including revenue, profit, loss and more.

Value in ₹ crore
DetailsQ'2 23Q'3 23Q'4 23Q'1 24Q'2 24
Revenue₹347.55Cr (-)₹231.05Cr (↓33.52%)₹219.82Cr (↓4.86%)₹252.93Cr (↑15.06%)₹230.69Cr (↓8.79%)
Net Income₹120.59Cr (-)₹79.56Cr (↓34.02%)₹46.75Cr (↓41.24%)₹53.37Cr (↑14.16%)₹60.77Cr (↑13.87%)
Net Profit Margin34.70% (-)34.43% (↓0.78%)21.27% (↓38.22%)21.10% (↓0.80%)26.34% (↑24.83%)
Value in ₹ crore
Details2019202020212022
Total Assets₹793.38Cr (-)₹1,112.82Cr (↑40.26%)₹1,361.30Cr (↑22.33%)₹1,806.37Cr (↑32.69%)
Total Liabilities₹203.09Cr (-)₹329.99Cr (↑62.48%)₹296.11Cr (↓10.27%)₹285.67Cr (↓3.53%)
Value in ₹ crore
Details2019202020212022
Operating Cash Flow₹50.40Cr (-)₹358.75Cr (↑611.81%)₹328.84Cr (↓8.34%)₹269.89Cr (↓17.93%)

Suven Pharmaceuticals Ltd Index Inclusions

BSE 500

₹34,765.79

0 (▲0%)

Nifty Smallcap 250

₹15,639.70

0.21 (▲32.55%)

Nifty 500

₹0.00

0 (▲0%)

S&P BSE SmallCap Select

₹7,178.77

0 (▲0%)

BSE Healthcare

₹42,555.65

0 (▲0%)

BSE Small-Cap

₹48,193.46

0 (▲0%)

S&P BSE 250 SmallCap

₹6,257.98

0 (▲0%)

S&P BSE 400 MidSmallCap

₹11,171.57

0 (▲0%)

Nifty MNC

₹26,910.00

-0.05 (▲-12.7%)

Nifty MidSmallcap 400

₹18,431.30

0.21 (▲38.8%)

S&P BSE AllCap

₹10,471.31

0 (▲0%)

Suven Pharmaceuticals Ltd Shareholding Pattern

View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Suven Pharmaceuticals Ltd.

InvestorsHoldings %Quarterly Trend3M change
Promoter Holdings
60%
0.00
Foreign Institutions
9.47%
0.00
Mutual Funds
8.56%
0.00
Retail Investors
19.1%
0.00
Others
2.87%
0.00

Suven Pharmaceuticals Ltd vs Peers

Compare market cap, revenue, PE, and other key metrics of Suven Pharmaceuticals Ltd with its industry peers.

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd
BUY₹29,264.79 Cr142.95%0.53NANA
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd
NA₹14,628.52 Cr41.85%0.64NANA
Rainbow Childrens Medicare Ltd
Rainbow Childrens Medicare Ltd
BUY₹15,546.04 Cr48.01%0.73NANA
Poly Medicure Ltd
Poly Medicure Ltd
BUY₹21,699.41 Cr158.35%0.55NANA
Wockhardt Ltd
Wockhardt Ltd
NA₹21,434.28 Cr91.89%0.74NANA
See all

Suven Pharmaceuticals Ltd News & Key Events

Latest news and events at one place to help you take investing decisions in Suven Pharmaceuticals Ltd.

  • Suven Pharmaceuticals Merger with Cohance Approved - 25 Apr, 2025

    The merger between Suven Pharmaceuticals and Cohance Lifesciences will take effect on May 1, 2025, aiming to create a diversified CDMO platform. The National Company Law Tribunal approved the merger on March 27, with plans for aggressive expansion and a revenue target of Rs 6000 crore by FY29.

  • Suven Pharma Advances with Merger and Global Engagement - 23 Apr, 2025

    Suven Pharmaceuticals received regulatory approval for increasing foreign investment post-merger with Cohance Lifesciences. The company also sees heightened interest from global pharma firms seeking alternatives to China.

  • Goldman Sachs Initiates Buy Rating for Suven Pharma - 08 Apr, 2025

    Goldman Sachs has initiated coverage on Suven Pharmaceuticals with a Buy rating and a target price of ₹1,350, anticipating structural growth starting FY26 driven by key drugs and successful acquisitions. The brokerage projects over 20% CAGR in EBITDA for the combined entity, highlighting a strong recovery path and improving profitability.

  • Suven Pharmaceuticals Receives NSE Caution on Disclosure - 02 Apr, 2025

    Suven Pharmaceuticals Ltd received a caution from the NSE for delaying the disclosure of its Statutory Auditors' appointment. The company assures no impact on its operations and commits to future compliance with SEBI regulations.

  • Suven Pharmaceuticals Merges with Cohance Lifesciences - 28 Mar, 2025

    Suven Pharmaceuticals has received NCLT approval for its merger with Cohance Lifesciences, creating a diversified CDMO platform. The merger aims to enhance global capabilities and is expected to generate $1 billion in revenue within five years.

Insights on Suven Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 10.84% to 11.05% in Mar 2025 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, SUVENPHAR stock has moved up by 76.5%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, SUVENPHAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 5 quarters, 46.75 Cr → 82.88 Cr (in ₹), with an average increase of 12.9% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 248.85 Cr → 322.86 Cr (in ₹), with an average increase of 12.1% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 46.7%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 50.10% of holdings in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 13.15% to 13.04% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 22.37% to 22.23% in Mar 2025 quarter

About Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Limited (SPL) is a biopharmaceutical company engaged in the development and manufacturing of New Chemical Entity (NCE) based Intermediates and Active Pharmaceutical Ingredients, Speciality Chemicals, and formulated drugs. In 2019, Suven Life Sciences Ltd. transferred the CRAMS business to the Company, and the equity shares of the Company were listed for trading in March 2020. The Board approved and recommended the issue of 1:1 bonus shares in August 2020, and the number of shares increased from 127,282,478 to 254,564,956. In 2021, Suven invested 120 crore in investing and has a capex plan of Rs.320crore. In 2022, the Company also filed 17 ANDAs for which 9 were approved and 8 products were launched. The Company acquired 100 stake in Casper Pharma Private Limited in 2022, making it a Wholly Owned Subsidiary. In this way, Suven Pharmaceuticals Limited is endeavouring to be the leading biopharmaceutical company in global markets.

Revenue: ₹230.69Cr as on June 2024 (Q2 24)
Net Profit: ₹60.77Cr as on June 2024 (Q2 24)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
OrganisationSuven Pharmaceuticals Ltd
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Indian Mutual Funds that own Suven Pharmaceuticals Ltd

Check out the Mutual Funds with significant holdings in Suven Pharmaceuticals Ltd.

Futures and Options

View the latest movement in Suven Pharmaceuticals Ltd Futures & Options, including strike prices, expiry dates, and percentage changes.

FAQs

What is Suven Pharmaceuticals Ltd price today?

Suven Pharmaceuticals Ltd share price today stands at ₹1136.4, Open: ₹1160, Previous Close: ₹1148.7, High: ₹1165.9, Low: ₹1122, 52 Week High: ₹1360, 52 Week Low: ₹598.

How to Buy Suven Pharmaceuticals Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Suven Pharmaceuticals Ltd shares

What are today's traded volumes of Suven Pharmaceuticals Ltd?

Today's traded volume of Suven Pharmaceuticals Ltd(SUVENPHAR) is 79.16K.

What is today's market capitalisation of Suven Pharmaceuticals Ltd?

Today's market capitalisation of Suven Pharmaceuticals Ltd(SUVENPHAR) is ₹29,264.79 Cr.

What is the 52 Week High and Low Range of Suven Pharmaceuticals Ltd?

Suven Pharmaceuticals Ltd (SUVENPHAR)
Price
52 Week High
₹1360
52 Week Low
₹598

How much percentage Suven Pharmaceuticals Ltd is down from its 52 Week High?

Suven Pharmaceuticals Ltd (SUVENPHAR) share price is ₹1136.4. It is down -16.44% from its 52 Week High price of ₹1360

How much percentage Suven Pharmaceuticals Ltd is up from its 52 Week low?

Suven Pharmaceuticals Ltd (SUVENPHAR) share price is ₹1136.4. It is up 90.03% from its 52 Week Low price of ₹598